Minor ginsenoside F1 improves memory in APP/PS1 mice

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Ginseng is known for cognitive benefits, attributed to ginsenosides.
• Major ginsenosides show memory-enhancing effects, but minor ones are less understood.
• Alzheimer's disease (AD) involves cognitive decline and amyloid-beta (Aβ) plaque accumulation.

Purpose of the Study:

• To investigate the memory-enhancing effects of minor ginsenoside F1 in an AD mouse model.
• To explore the underlying molecular mechanisms of F1's action on Aβ plaques and memory-related proteins.

Main Methods:

• Oral administration of ginsenoside F1 jelly to APPswe/PSEN1dE9 (APP/PS1) mice for 8 weeks.
• Assessment of spatial working memory and context-dependent fear memory.
• Analysis of Aβ plaque burden in the cortex and hippocampus.
• Western blot analysis of phosphorylated CREB and BDNF levels.

Main Results:

• Ginsenoside F1 administration restored spatial working memory in AD mice.
• F1 reduced Aβ plaque area and density in the cortex, but not the hippocampus.
• F1 normalized reduced phosphorylated CREB levels in the hippocampus.
• F1 augmented BDNF levels in the cortex.

Conclusions:

• Minor ginsenoside F1 demonstrates therapeutic potential for Alzheimer's disease.
• F1 may exert its effects by reducing Aβ pathology and modulating CREB and BDNF pathways.
• Further research into F1 as a therapeutic agent for AD is warranted.